The current price of INO is $1.45 — it has decreased by 10.49% since the previous close. Data as of Nov 5, 2026.
INO is up 67.88% over the past week, up 26.09% over the past month and down 36.68% over the past year. The price is above its 200-day moving average of $1.27.
Analysts' average 12-month price target for INO is $4.00, which implies 175.86% upside from the current price. Individual estimates range from $3.00 to $5.00.
Of the 4 analysts covering Inovio Pharmaceuticals, Inc., 1 rates it a strong buy, 2 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Inovio Pharmaceuticals, Inc. has a market capitalization of $100.18M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Inovio Pharmaceuticals, Inc. posted a loss of $0.07 per share against an estimate of -$0.2167, beating expectations by 67.69%. Upcoming reports are listed in the earnings calendar.
Inovio Pharmaceuticals, Inc. has not paid any dividends over the past year.
Companies most comparable to Inovio Pharmaceuticals, Inc. include Opus Genetics, Inc., Agenus Inc., Alector, Inc., Fate Therapeutics, Inc. and Seer, Inc.
In the latest trading session INO moved between $1.40 and $1.59, a range of 13.10% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Inovio Pharmaceuticals, Inc. shows a buy rating today and a buy rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks INO has traded between $0.5632 and $2.72. The current price is 46.69% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.